F-18-FDG Imaging for Atherosclerotic Plaque Characterization

Current Cardiovascular Imaging Reports

Volumn 4, Issue 3, 2011, Pages 190-198

  Wenning, Christian ^a,b   Stegger, Lars ^b   Hermann, Sven ^a   Schober, Otmar ^b   Schäfers, Michael ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Atherosclerosis; FDG PET; Inflammation; Macrophages; Plaque

Indexed keywords

EID: 84855463970     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-011-9083-7     Document Type: Review

References (62)

1. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction. An update on the framingham study. N Engl J Med. 1984; 311: 1144-7.
2. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988; 78: 1157-66.
3. Giroud D, Li JM, Urban P, et al. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol. 1992; 69: 729-32.
4. Schoenhagen P, Ziada KM, Kapadia SR, et al. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation. 2000; 101: 598-603.
5. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation. 1995; 92: 2333-42.
6. • Hansson GK: Atherosclerosis--an immune disease: the anitschkov lecture 2007. Atherosclerosis. 2009; 202: 2-10. This article reviewed the current pathophysiological idea of atherosclerosis as an immune disease on the basis of patient studies (including epidemiological cohorts) and experimental animal models.
7. •• Schäfers M, Schober O, Hermann S. Matrix-metalloproteinases as imaging targets for inflammatory activity in atherosclerotic plaques. J Nucl Med. 2010; 51: 663-6. This review article is about molecular targets in atherosclerotic plaques, particularly matrix-metalloproteinases. Besides rather unspecific FDG-PET imaging, the development of target-specific and/or cell-specific molecular imaging promises substantial clinical innovations and improvements.
8. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004; 231: 305-32.
9. Sheikine Y, Di Carli MF. Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure. Curr Heart Fail Rep. 2008; 5: 136-42.
10. Bleeker-Rovers CP, Vos FJ, Corstens FH, Oyen WJ. Imaging of infectious diseases using [18F] fluorodeoxyglucose PET. Q J Nucl Med Mol Imaging. 2008; 52: 17-29.
11. Weisdorf DJ, Craddock PR, Jacob HS. Granulocytes utilize different energy sources for movement and phagocytosis. Inflammation. 1982; 6: 245-56.
12. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: Angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009; 218: 7-29.
13. Strauss HW, Dunphy M, Tokita N. Imaging the vulnerable plaque: a scintillating light at the end of the tunnel? J Nucl Med. 2004; 45: 1106-7.
14. Shepherd PR, Kahn BB. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999; 341: 248-57.
15. Newsholme P, Curi R, Gordon S, Newsholme EA. Metabolism of glucose, glutamine, long-chain fatty acids and ketone bodies by murine macrophages. Biochem J. 1986; 239: 121-5.
16. Mamede M, Higashi T, Kitaichi M, et al. [18F]FDG uptake and PCNA, glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005; 7: 369-79.
17. Taneja N, Coy PE, Lee I, et al. Proinflammatory interleukin-1 cytokines increase mesangial cell hexokinase activity and hexokinase II isoform abundance. Am J Physiol Cell Physiol. 2004; 287: C548-57.
18. Fu Y, Maianu L, Melbert BR, Garvey WT. Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: a role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation. Blood Cells Mol Dis. 2004; 32: 182-90.
19. Maschauer S, Prante O, Hoffmann M, et al. Characterization of 18F-FDG uptake in human endothelial cells in vitro. J Nucl Med. 2004; 45: 455-60.
20. Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology. 1992; 183: 643-7.
21. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002; 105: 2708-11.
22. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992; 258: 468-71.
23. Vallabhajosula S, Fuster V. Atherosclerosis: Imaging techniques and the evolving role of nuclear medicine. J Nucl Med. 1997; 38: 1788-96.
24. Tawakol A, Migrino RQ, Hoffmann U, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol. 2005; 12: 294-301.
25. Aziz K, Berger K, Claycombe K, et al. Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography. Circulation. 2008; 117: 2061-70.
26. • Zhao Y, Kuge Y, Zhao S, et al. Prolonged high-fat feeding enhances aortic 18F-FDG and 99mTc-annexin A5 uptake in apolipoprotein E-deficient and wild-type C57BL/6J mice. J Nucl Med. 2008; 49: 1707-14. This experimental animal study indicates a correlation between hypercholesterolemia (cholesterol loading of ApoE-/- mice over time) and F-18-FDG accumulation in murine aortas.
27. Laitinen I, Marjamaki P, Haaparanta M, et al. Non-specific binding of [18F]FDG to calcifications in atherosclerotic plaques: experimental study of mouse and human arteries. Eur J Nucl Med Mol Imaging. 2006; 33: 1461-7.
28. Laurberg JM, Olsen AK, Hansen SB, et al. Imaging of vulnerable atherosclerotic plaques with FDG-microPET: no FDG accumulation. Atherosclerosis. 2007; 192: 275-82.
29. Ogawa M, Magata Y, Kato T, et al. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med. 2006; 47: 1845-50.
30. Worthley SG, Zhang ZY, Machac J, et al. In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis. Int J Cardiovasc Imaging. 2009; 25: 251-7.
31. Yun M, Yeh D, Araujo LI, et al. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med. 2001; 26: 314-9.
32. Davies JR, Rudd JH, Fryer TD, et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke. 2005; 36: 2642-7.
33. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006; 48: 1818-24.
34. • Tahara N, Kai H, Nakaura H, et al. The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography. Eur Heart J. 2007; 28: 2243-8. The presence of atherosclerosis alone does not predict the inflammatory status. This clinical study evaluated the frequency of inflammatory activity in carotid artery plaques by F-18-FDG PET. Inflammation was visualized by FDG-PET imaging in approximately 30% of patients with documented carotid atherosclerosis.
35. Dunphy MP, Schoder H, Strauss HW. Radionuclide techniques for identifying vulnerable plaque. J Nucl Med. 2007; 48: 1753-5.
36. •• Rudd JH, Myers KS, Bansilal S, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging. 2009; 2: 107-15. This clinical study evaluated correlations between atherosclerotic plaque inflammation assessed by FDG PET and plaque calcification, serum biomarkers, and vascular risk factors. The authors suggest that FDG PET imaging could be used as a surrogate marker of atherosclerotic disease activity and for clinical risk prediction.
37. Okane K, Ibaraki M, Toyoshima H, et al. 18F-FDG accumulation in atherosclerosis: use of CT and MR co-registration of thoracic and carotid arteries. Eur J Nucl Med Mol Imaging. 2006; 33: 589-94.
38. •• Rudd JH, Myers KS, Bansilal S, et al. (18)fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007; 50: 892-6. This study evaluated the reproducibility of FDG PET findings by serial PET measurements. Spontaneous change in plaque FDG uptake was low over 2 weeks, with favorable interobserver and intraobserver agreement.
39. Graebe M, Pedersen SF, Borgwardt L, et al. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2009; 37: 714-21.
40. Pedersen SF, Graebe M, Fisker Hag AM, et al. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun. 2010; 31: 423-9.
41. Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology. 2003; 229: 831-7.
42. Yun M, Jang S, Cucchiara A, et al. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med. 2002; 32: 70-6.
43. Tahara N, Kai H, Yamagishi S, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007; 49: 1533-9.
44. • Wu YW, Kao HL, Chen MF, et al. Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J Nucl Med. 2007; 48: 227-33. This study indicated a link between 18-F-FDG uptake and levels of circulating MMP-1. The authors suppose that 18-F-FDG PET/CT could be used as an adjunct to the clinical management of high-risk atherosclerosis and an in vivo tool to study plaque biology.
45. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002; 90: 251-62.
46. Schäfers M, Riemann B, Kopka K, et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation. 2004; 109: 2554-9.
47. Wagner S, Breyholz HJ, Höltke C, et al. A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies. Appl Radiat Isot. 2009; 67: 606-10.
48. Williams G, Kolodny GM. Retrospective study of coronary uptake of 18F-fluorodeoxyglucose in association with calcification and coronary artery disease: a preliminary study. Nucl Med Commun. 2009; 30: 287-91.
49. • Paulmier B, Duet M, Khayat R, et al. Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol. 2008; 15: 209-17. This clinical study showed a correlation between the extent of arterial 18-FDG uptake and the occurrence of recent cardiovascular events, a hint toward a possible prognostic value of 18-F-FDG PET imaging.
50. Rominger A, Saam T, Wolpers S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009; 50: 1611-20.
51. Muntendam P, McCall C, Sanz J, et al. High-risk plaque initiative. The BIOIMAGE study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease--study design and objectives. Am Heart J. 2010; 160: 49-57. e1.
52. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006; 48: 1825-31.
53. • Lee SJ, On YK, Lee EJ, et al. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med. 2008; 49: 1277-82. This clinical study indicated that 18-F-FDG uptake is correlated to hypercholesterolemia in patients. Moreover, pre-existing vascular 18-F-FDG uptake was reduced over time in correlation to increases in plasma HDL levels achieved by lifestyle intervention. Thus, the authors suppose, serial 18-F-FDG PET/CT may be useful for monitoring improvements in the inflammatory component of atherosclerotic lesions in response to risk modification.
54. Kato K, Schober O, Ikeda M, et al. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur J Nucl Med Mol Imaging. 2009; 36: 1622-8.
55. Laitinen IE, Luoto P, Nagren K, et al. Uptake of 11C-choline in mouse atherosclerotic plaques. J Nucl Med. 2010; 51: 798-802.
56. Forster S, Rominger A, Saam T, et al. 18F-fluoroethylcholine uptake in arterial vessel walls and cardiovascular risk factors: correlation in a PET-CT study. Nuklearmedizin. 2010; 49: 148-53.
57. Dunphy MP, Freiman A, Larson SM, Strauss HW. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med. 2005; 46: 1278-84.
58. Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009; 50: 563-8.
59. Rogers IS, Nasir K, Figueroa AL, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging. 2010; 3: 388-97.
60. Buther F, Dawood M, Stegger L, et al. List mode-driven cardiac and respiratory gating in PET. J Nucl Med. 2009; 50: 674-81.
61. Martinez-Moller A, Zikic D, Botnar RM, et al. Dual cardiac-respiratory gated PET: implementation and results from a feasibility study. Eur J Nucl Med Mol Imaging. 2007; 34: 1447-54.
62. Wasselius J, Larsson S, Sundin A, Jacobsson H. Assessment of inactive, active and mixed atherosclerotic plaques by 18F-FDG-PET; an age group-based correlation with cardiovascular risk factors. Int J Cardiovasc Imaging. 2009; 25: 133-40.